Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Assembly Biosciences, Inc.
Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection
June 18, 2024
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Announces $12.6 Million in Equity Financings
June 17, 2024
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366
June 10, 2024
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024
June 05, 2024
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024
May 22, 2024
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
May 08, 2024
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
March 28, 2024
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Announces Effective Date of Reverse Stock Split
February 08, 2024
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Provides Anticipated Development Milestones for 2024
January 04, 2024
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®
November 10, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates
November 08, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer
November 08, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences to Present New Data at AASLD The Liver Meeting®
October 11, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor
October 02, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting
September 19, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Reports Second Quarter 2023 Financial Results and Recent Updates
August 09, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop
July 17, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASL’s International Liver Congress™ 2023
June 21, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023
June 07, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference
May 23, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights
May 04, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Announces Additional Promising Data from Phase 1a Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate ABI-4334 and Provides Pipeline Update
April 18, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights
March 22, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes
February 15, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334
December 19, 2022
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334
November 14, 2022
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation
November 08, 2022
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV
November 04, 2022
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting®
October 24, 2022
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit